Anoro Ellipta (Umeclidinium/Vilanterol) Shortage Update: What Patients Need to Know in 2026

If you've had trouble filling your Anoro Ellipta prescription in recent months, you're not imagining it. Many COPD patients across the country are experiencing inconsistent availability of this once-daily maintenance inhaler. Here's a current, fact-based look at what's happening and what it means for you.

Is Anoro Ellipta on the FDA Shortage List in 2026?

As of 2026, Anoro Ellipta (umeclidinium/vilanterol 62.5/25 mcg) is NOT listed on the FDA's official drug shortage database. This means the federal government has not declared a recognized national supply crisis for this medication.

However, the absence from the FDA shortage list does not mean the drug is easy to find everywhere. Many patients report that their pharmacy is "out of stock" or must "special order" the medication — experiences that feel like a shortage even if one isn't formally declared.

What's Causing Availability Problems in 2026?

Several factors are contributing to inconsistent Anoro Ellipta availability at the pharmacy level:

The Brand-to-Generic Transition

The biggest development affecting Anoro Ellipta availability in 2025-2026 was the launch of an FDA-approved authorized generic manufactured by Prasco Laboratories. While this is ultimately positive — more competition, potentially lower prices — the transition period often disrupts supply chains at the pharmacy level. Some pharmacies have shifted to stocking only the generic; others carry only the brand; and many are in transition. Patients asking specifically for "Anoro Ellipta" may be turned away even when the generic equivalent is available right there.

Specialized Manufacturing Requirements

The Ellipta dry powder inhaler device is more complex to manufacture than standard oral medications. Each inhaler contains two separate foil blister strips — one for umeclidinium and one for vilanterol — that must be precisely synchronized. Production disruptions at any point in GlaxoSmithKline's manufacturing or distribution chain can create downstream pharmacy shortages.

39,453+ patients found their medications in stock

39K+

Find Umeclidinium/Vilanterol In Stock Today →

Variable Pharmacy Stocking Practices

Not all pharmacies stock all medications. COPD inhalers like Anoro Ellipta are stocked based on local patient demand. Large chain pharmacies in areas with fewer COPD patients may not keep Anoro in regular inventory. Independent pharmacies and specialty respiratory pharmacies tend to maintain more consistent stock.

Insurance Formulary Changes

Some Medicare Part D and commercial insurance plans have adjusted their formulary coverage for Anoro Ellipta — moving it to higher tiers, adding prior authorization requirements, or preferring the authorized generic. When insurers push patients toward different products, it affects how pharmacies stock the brand-name version.

Skip the calls, skip the stress.

Find Umeclidinium/Vilanterol In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

What Does This Mean for COPD Patients?

For patients with moderate-to-severe COPD, missing a dose of Anoro Ellipta is more than an inconvenience. This medication is your maintenance bronchodilator — skipping it can lead to worsening breathlessness, decreased exercise tolerance, and in some cases, a COPD exacerbation that requires emergency care.

That's why having a plan before you run out matters. Don't wait until your inhaler is empty to look for a refill.

What Should Patients Do Right Now?

• Check availability proactively: Use medfinder to have pharmacies called on your behalf. medfinder searches for pharmacies near you that can fill your Anoro Ellipta prescription and texts you the results.
• Ask about the generic: When contacting pharmacies, ask specifically for "umeclidinium/vilanterol 62.5/25 mcg" or the Prasco generic. Don't limit yourself to searching only for "Anoro Ellipta."
• Refill early: Start looking for your refill when your dose counter reaches 15-20, not when it hits zero.
• Consider switching to mail order: A 90-day mail-order supply can eliminate the month-to-month pharmacy search entirely.
• Have a backup plan: Talk to your doctor about a temporary alternative LAMA/LABA inhaler (such as Stiolto Respimat) that you could switch to if Anoro Ellipta is unavailable for an extended period.
• Always keep your rescue inhaler available: Anoro Ellipta is a maintenance medication, not a rescue inhaler. Make sure you always have a short-acting bronchodilator (like albuterol) on hand for sudden breathing problems.

Looking Ahead: Will Availability Improve?

The authorized generic launch is expected to improve Anoro Ellipta's overall availability over time by adding a second manufacturing source. As pharmacies and wholesalers complete their transition to stocking the generic alongside the brand, patients should see more consistent availability. In the meantime, the most reliable strategy is proactive planning and using tools that can check multiple pharmacies on your behalf.

The Bottom Line

Anoro Ellipta is not in an official FDA shortage in 2026, but inconsistent pharmacy stocking — driven largely by the brand-to-generic transition — is creating real availability challenges for COPD patients. The drug exists nationally; it just may not be at your first pharmacy. For a deeper explanation of why, see our article on why Anoro Ellipta is hard to find. And if you need it now, use medfinder to find a pharmacy that can fill your prescription today.